[HTML][HTML] Engineering interferons and interleukins for cancer immunotherapy
Cytokines are a class of potent immunoregulatory proteins that are secreted in response to
various stimuli and act locally to regulate many aspects of human physiology and disease …
various stimuli and act locally to regulate many aspects of human physiology and disease …
Antibody targeted drugs as cancer therapeutics
Abstract Treatment of cancer is a double-edged sword: it should be as aggressive as
possible to completely destroy the tumour, but it is precisely this aggressiveness which often …
possible to completely destroy the tumour, but it is precisely this aggressiveness which often …
Tumor regression by targeted gene delivery to the neovasculature
JD Hood, M Bednarski, R Frausto, S Guccione… - Science, 2002 - science.org
Efforts to influence the biology of blood vessels by gene delivery have been hampered by a
lack of targeting vectors specific for endothelial cells in diseased tissues. Here we show that …
lack of targeting vectors specific for endothelial cells in diseased tissues. Here we show that …
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis
VEGF is unique among angiogenic growth factors because it disrupts endothelial barrier
function. Therefore, we considered whether this property of VEGF might contribute to tumor …
function. Therefore, we considered whether this property of VEGF might contribute to tumor …
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer
G Spizzo, G Gastl, P Obrist, P Went, S Dirnhofer… - Breast cancer research …, 2004 - Springer
Previous studies in small series of patients with invasive breast cancer suggested a
prognostic value of Ep-CAM overexpression in primary tumor tissue. To corroborate these …
prognostic value of Ep-CAM overexpression in primary tumor tissue. To corroborate these …
Immunocytokines: a novel class of potent armed antibodies
N Pasche, D Neri - Drug discovery today, 2012 - Elsevier
Several cytokines have been investigated in clinical trials, based on their potent therapeutic
activity observed in animal models of cancer and other diseases. However, substantial …
activity observed in animal models of cancer and other diseases. However, substantial …
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
C Hutmacher, D Neri - Advanced drug delivery reviews, 2019 - Elsevier
Cytokines have long been used for therapeutic applications in cancer patients. Substantial
side effects and unfavorable pharmacokinetics limit their application and may prevent dose …
side effects and unfavorable pharmacokinetics limit their application and may prevent dose …
Engineering antibodies for therapy
LG Presta - Current pharmaceutical biotechnology, 2002 - ingentaconnect.com
With eleven therapeutic antibodies approved worldwide and many more in clinical trials,
research on antibody engineering has continued to escalate and expand. This review …
research on antibody engineering has continued to escalate and expand. This review …
Antibody–cytokine fusion proteins for the therapy of cancer
ML Penichet, SL Morrison - Journal of immunological methods, 2001 - Elsevier
Advances in genetic engineering and expression systems have led to rapid progress in the
development of antibodies fused to other proteins. These 'antibody fusion proteins' have …
development of antibodies fused to other proteins. These 'antibody fusion proteins' have …
Facts and hopes on chimeric cytokine agents for cancer immunotherapy
Cytokines are key mediators of immune responses that can modulate the antitumor activity
of immune cells. Cytokines have been explored as a promising cancer immunotherapy …
of immune cells. Cytokines have been explored as a promising cancer immunotherapy …